Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer

Combination therapy of lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, a monoclonal antibody targeting programmed death receptor 1 (PD-1), was recently approved by the Food and Drug Administration for therapy of advanced endometrial cancer. This case series highlight...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Clarissa, Sarasohn, Debra, Weigelt, Britta, Zamarin, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448068/
https://www.ncbi.nlm.nih.gov/pubmed/37636495
http://dx.doi.org/10.1016/j.gore.2023.101258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448068/
https://www.ncbi.nlm.nih.gov/pubmed/37636495
http://dx.doi.org/10.1016/j.gore.2023.101258

Ejemplares similares